Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
British Journal of Haematology|March 13, 2020
Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group modelRoman Hájek, Viera Sandecka, Ivan Špička, et al.
Annals of Hematology|August 18, 2025
De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysisMartin Stork, Jakub Radocha, Jana Mihalyova, et al.
Cancer Medicine|June 23, 2018
Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal GammopathiesJakub Radocha, Vladimír Maisnar, Luděk Pour, et al.
Leukemia Research|July 13, 2013
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma GroupJiri Minarik, Viera Sandecka, Vladimir Maisnar, et al.
European Journal of Haematology|July 17, 2021
Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry DataViera Sandecká, Luděk Pour, Ivan Špička, et al.
Plos One|April 16, 2015
Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathyJiri Minarik, Petr Pavlicek, Ludek Pour, et al.
European Journal of Haematology|October 11, 2024
Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow CytometryLudmila Muronova, Ondrej Soucek, David Zihala, et al.
American Journal of Hematology|June 10, 2024
Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myelomaSosana Delimpasi, Meletios A Dimopoulos, Jan Straub, et al.
BMC Cancer|January 16, 2021
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practiceJiri Minarik, Tomas Pika, Jakub Radocha, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2025
Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 AntibodiesAlexandra Jungova, Martin Stork, Ivan Spicka, et al.
Pageof 4